Dr Moira Cruickshank
Research Fellow
- ºÚÁÏÍø
-
- Email Address
- m.cruickshank@abdn.ac.uk
- Office Address
Health Services Research Unit
3rd Floor Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I joined the Knowledge Synthesis team of ACE following completion of my PhD in 2011. I have worked on a wide range of technology assessment appraisals and health technology assessment reviews.
Qualifications
- PhD Health Psychology2011 - ºÚÁÏÍø
- Publications
-
Page 2 of 6 Results 11 to 20 of 56
The effects and safety of testosterone replacement therapy for men with hypogonadism: The TestES evidence synthesis and economic evaluation
Health Technology Assessment, vol. 28, no. 43Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
What is the impact of long-term COVID-19 on workers in healthcare settings? A rapid systematic review of current evidence
PloS ONE, vol. 19, no. 3 , e0299743Contributions to Journals: Review articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Cost-effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels
Andrology, vol. 12, no. 3, pp. 477-486Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
National Institute for Health and Care Excellence (NICE). 20 pagesBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
- [ONLINE]
Netarsudil-latanoprost for previously treated openangle glaucoma or ocular hypertension [ID1363]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
Clinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo:: Results Of Individual Patient And Aggregate Data Meta-analyses
Annual Meeting of the Endocrine Society 2023, bvad114.1704Contributions to Journals: Abstracts- [ONLINE] DOI:
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
The Lancet Healthy Longevity, vol. 4, no. 10, pp. e561-e572Contributions to Journals: Articles- [ONLINE]
- [ONLINE] DOI:
- [OPEN ACCESS]
Deucravacitinib for treating moderate-to-severe plaque psoriasis
Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. 155 pagesBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]
Secukinumab for Moderate-to-Severe Hidradenitis Suppurativa [ID4039]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports- [ONLINE]
- [ONLINE]